Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Actinium Pharmaceuticals Inc (ATNM)

Actinium Pharmaceuticals Inc (ATNM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 143,899
  • Shares Outstanding, K 23,785
  • Annual Sales, $ 1,140 K
  • Annual Income, $ -24,770 K
  • 60-Month Beta 0.31
  • Price/Sales 126.41
  • Price/Cash Flow N/A
  • Price/Book 1.96
Trade ATNM with:

Options Overview Details

View History
  • Implied Volatility 105.58% ( -23.27%)
  • Historical Volatility 92.06%
  • IV Percentile 58%
  • IV Rank 36.98%
  • IV High 158.29% on 04/20/22
  • IV Low 74.65% on 06/24/21
  • Put/Call Vol Ratio 0.41
  • Today's Volume 984
  • Volume Avg (30-Day) 380
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 14,613
  • Open Int (30-Day) 20,671

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate 0.55
  • Number of Estimates 2
  • High Estimate 1.28
  • Low Estimate -0.18
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +320.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.09 +16.31%
on 05/11/22
7.03 -15.79%
on 04/25/22
-0.94 (-13.70%)
since 04/22/22
3-Month
4.41 +34.24%
on 03/15/22
7.49 -20.96%
on 04/12/22
+1.16 (+24.37%)
since 02/23/22
52-Week
4.41 +34.24%
on 03/15/22
10.30 -42.52%
on 09/24/21
-2.12 (-26.37%)
since 05/21/21

Most Recent Stories

More News
Has Alkermes (ALKS) Outpaced Other Medical Stocks This Year?

Here is how Alkermes (ALKS) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

ALKS : 29.30 (-2.33%)
ATNM : 5.92 (-2.15%)
Actinium (ATNM) Up on Commercialization Deal With Immedica

Actinium (ATNM) out-licenses exclusive rights to Iomab-B, an antibody radiation conjugate for facilitating bone-marrow transplant, to Immedica in Europe, the Middle East and North African countries.

ANGN : 1.2400 (-3.12%)
COLL : 15.65 (-4.34%)
ATNM : 5.92 (-2.15%)
ASRT : 3.09 (-1.90%)
Biotech Stocks News: What’s Going on With LIXT, PTE, QLGN and ATNM Stocks Today

Microcap biotech stocks are skyrocketing today. Here are the names investors need to know.

SBFM : 1.6000 (-7.51%)
PTE : 2.43 (+3.40%)
QLGN : 0.5320 (+4.31%)
LIXT : 0.7993 (-3.16%)
ATNM : 5.92 (-2.15%)
Relative Strength Alert For Actinium Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

ATNM : 5.92 (-2.15%)
Is Apria (APR) Stock Outpacing Its Medical Peers This Year?

Here is how Apria (APR) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

APR : 37.50 (+0.03%)
ATNM : 5.92 (-2.15%)
Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90+ Companies

Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand...

AZ.TO : 6.19 (unch)
AAZZF : 10.8545 (+0.13%)
ACST : 0.9080 (-1.91%)
ATNM : 5.92 (-2.15%)
ADCO.TO : 0.2750 (-3.51%)
ADCOF : 0.2137 (-7.09%)
ALIM : 5.40 (+7.78%)
ACOGF : 0.5880 (-0.51%)
AMST : 0.5626 (-3.00%)
ANVS : 8.98 (-1.86%)
ANPC : 0.3110 (+3.70%)
ARC : 2.89 (-1.03%)
Anthem, Inc. To Acquire myNEXUS, Home Health Benefits Manager

Anthem, Inc. (NYSE: ATNM) today announced that the company has entered into an agreement to acquire myNEXUS, Inc. (“myNEXUS”), a comprehensive home-based nursing management company for payors. myNEXUS...

ANTM : 494.85 (+0.41%)
ATNM : 5.92 (-2.15%)
Promising New Cancer Treatments Advancing Through The Pipeline In Over $200 Billion Dollar Drug Market

Palm Beach, FL – October 21, 2020 – Cancer immunotherapy has emerged as a new avenue for revenue generation for pharmaceutical companies. Adverse effects, such as recurrence of cancer and organ failure,...

ATNM : 5.92 (-2.15%)
AZN : 66.41 (+0.30%)
BMY : 76.70 (+0.67%)
MRK : 93.83 (+0.30%)
NWBO : 0.6850 (+0.75%)
Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy

NIH grant to support first of its kind clinical trial to use Antibody Radio-Conjugate for targeted conditioning prior to CAR T-cell therapy in patients with acute lymphoblastic leukemia and diffuse large...

ATNM : 5.92 (-2.15%)
LD Micro - 360 Companies Set to Present this Week

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online....

ACEYY : 3.9800 (-24.91%)
ISDR : 22.82 (+1.20%)
PLL.AX : 0.815 (-1.81%)
ACER : 2.26 (+3.20%)
ACRX : 0.2581 (+1.22%)
ACU : 32.93 (+2.91%)
ADIL : 1.3700 (+0.74%)
ADTX : 0.2701 (+0.04%)
ADXS : 0.0619 (-8.97%)
AEHR : 7.85 (unch)
AERG : 1.9300 (-4.69%)
AEY : 1.3800 (+5.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for their ARCs is targeted conditioning, which is intended...

See More

Key Turning Points

3rd Resistance Point 6.35
2nd Resistance Point 6.23
1st Resistance Point 6.07
Last Price 5.92
1st Support Level 5.80
2nd Support Level 5.68
3rd Support Level 5.53

See More

52-Week High 10.30
Fibonacci 61.8% 8.05
Fibonacci 50% 7.36
Fibonacci 38.2% 6.66
Last Price 5.92
52-Week Low 4.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar